Ascletis Pharma starts U.S. Phase I study for ASC36 obesity tablets
Ascletis Pharma Inc. has initiated a U.S. Phase I study for ASC36 oral tablets in obesity.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.